Form 8-K

8-K — PMGC Holdings Inc.

Accession: 0001213900-26-073986

Filed: 2026-07-01

Period: 2026-07-01

CIK: 0001840563

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0296527-8k_pmgc.htm (Primary)

EX-99.1 — PRESS RELEASE DATED JULY 1, 2026 (ea029652701ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0296527-8k_pmgc.htm · Sequence: 1

false

0001840563

2026-07-01

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):

July 1, 2026

PMGC Holdings Inc.

(Exact name of registrant as specified in its charter)

Nevada

001-41875

33-2382547

(State or other jurisdiction

of incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)

c/o 120 Newport Center Drive

Newport Beach, CA

92660

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (888) 445-4886

N/A

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant

to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value

ELAB

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On July 1, 2026, NorthStrive Biosciences Inc.,

a Delaware corporation and wholly owned subsidiary of PMGC Holdings Inc. (the “Company”), issued a press release, a copy of

which is furnished as Exhibit 99.1 to this Current Report on Form 8-K (“Form 8-K”).

The information furnished pursuant to this Item

7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,

as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated

by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly

set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release dated July 1, 2026.

104

Cover Page Interactive Data File (formatted in Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July

1, 2026

PMGC Holdings, Inc.

By:

/s/ Graydon Bensler

Name:

Graydon Bensler

Title:

Chief Executive Officer

EX-99.1 — PRESS RELEASE DATED JULY 1, 2026

EX-99.1

Filename: ea029652701ex99-1.htm · Sequence: 2

Exhibit 99.1

NorthStrive Biosciences Announces Positive Results from Phase

III of AI-Driven Drug Discovery Program with Yuva Biosciences

● Yuva Biosciences' proprietary MitoNova™ AI platform identified small-molecule

candidates that were biologically validated in primary human skeletal muscle cells, with multiple candidates increasing ANT1, a mitochondrial

protein central to skeletal muscle energy metabolism.

● Four AI-selected compounds demonstrated ANT1 induction, supporting their

further confirmatory testing and development.

NEWPORT BEACH, Calif., July 1, 2026 - NorthStrive

Biosciences Inc. ("NorthStrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) ("PMGC"

or the "Company"), today announced positive results from Phase III of its AI-driven drug discovery program with strategic

partner Yuva Biosciences, Inc. ("Yuva Biosciences").

Phase III of the parties’ drug discovery program (“Phase

III”) was designed to biologically validate a focused set of small-molecule candidates selected by Yuva Biosciences' proprietary

MitoNova™ AI platform. These candidates were tested in primary human skeletal muscle cells using an in vitro assay

measuring ANT1 protein expression.

ANT1 is a mitochondrial protein involved in cellular energy metabolism

in skeletal muscle. The parties’ drug discovery program is focused on identifying candidates that may support the Company's broader

development strategy around muscle preservation, including potential applications relevant to muscle health and metabolic stress.

The study in Phase III evaluated a focused set of AI-selected small-molecule

candidates. According to the results package prepared by Yuva Biosciences, four compounds (C1, C2, C3, and C4) increased ANT1 expression,

with the strongest candidates demonstrating dose-dependent induction. Yuva Biosciences’ results report identified C1, C2 and C4

as the strongest and most dose-consistent ANT1 inducers, while C3 also advanced as a candidate based on statistically significant activity

at the highest tested dose.

Key

Phase III Findings

Finding

Significance

Four AI-selected compounds significantly increased ANT1 expression.

C1, C2, C3 and C4 each demonstrated statistically significant increases in ANT1 expression, validating biological activity of multiple MitoNova™ AI-selected candidates in human skeletal muscle cells.

Multiple candidates demonstrated meaningful dose-dependent induction.

The strongest observed increases included C2 at up to +50%, C4 at up to +48%, and C1 at up to +46%, with C3 demonstrating a +29% increase at the highest tested dose.

The results support confirmatory testing and further development.

Yuva Biosciences recommended advancing the four validated candidates into a more mature and energy-demanding skeletal muscle model, to further confirm ANT1 induction and de-risk subsequent development.

Connection to Prior Program Update

The Company previously announced that Phase III was expected to use

Yuva Biosciences' improved sixth-generation classifier models to support a more refined selection of candidate compounds and a more comprehensive

in vitro validation stage. The prior update also stated that Phase III results were expected in Q2 2026. View

the prior PMGC press release.

Next Steps

Based on the positive Phase III results, NorthStrive Biosciences and

Yuva Biosciences are evaluating next steps, including confirmatory testing and further development of the four validated candidates. The

proposed next stage is expected to evaluate whether the ANT1 induction observed in primary human skeletal muscle cells is maintained in

a more mature muscle model that more closely reflects adult skeletal muscle biology.

About Yuva Biosciences, Inc.

Yuva Biosciences, Inc. is a mitochondrial sciences AI company that

uses advanced artificial intelligence to identify and develop therapeutic and natural candidates targeting aging-related pathways. Its

proprietary AI platform, MitoNova™, integrates proprietary biological, chemical, and mitochondrial-function datasets to accelerate

the discovery of compounds with the potential to improve cellular processes and overall tissue health. Multiple products incorporating

compounds discovered by Yuva Biosciences are already on the market, including Revive+ by BosleyMD. Yuva Biosciences is headquartered in

Birmingham, Alabama. For more information, please visit www.yuvabio.com.

About NorthStrive Biosciences Inc.

NorthStrive Biosciences Inc., a PMGC Holdings Inc. company, is a biopharmaceutical

company focused on the development and acquisition of cutting-edge aesthetic medicines. NorthStrive's lead asset, EL-22, leverages an

engineered probiotic approach to address the issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.

For more information, please visit www.northstrivebio.com.

About PMGC Holdings Inc.

PMGC Holdings Inc. is a diversified holding company that manages and

grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring

opportunities in multiple sectors to maximize growth and value. For more information, please visit www.pmgcholdings.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are

not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of

1995, as amended. Words such as "believes," "expects," "plans," "potential," "would"

and "future" or similar expressions such as "look forward" are intended to identify forward-looking statements. Forward-looking

statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead,

they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies,

projections, anticipated events and trends, the economy, activities of regulators and future regulations, the ability to obtain, maintain

and enforce patent protection, whether patent applications will issue or claims will be allowed, clinical and regulatory development timelines,

potential indications, safety and efficacy, and market opportunity. Because forward-looking statements relate to the future, they are

subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our

control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure

you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from

the anticipated results. Therefore, you should not rely on any of these forward-looking statements.

Forward-looking statements in this press release include, but are not

limited to, statements regarding the potential significance of the Phase III results, the potential advancement of candidate compounds,

future confirmatory testing, further characterization and development, the potential relevance of ANT1 induction, the Company's muscle

preservation strategy, and the potential applications or benefits of the AI-driven drug discovery program.

The results described in this press release are based on in vitro testing

and are preliminary in nature. The Company cannot provide assurance that any candidate will demonstrate similar activity in future testing,

differentiated models, animal studies, clinical studies, or any commercial application. There can be no assurance that the Company or

Yuva Biosciences will successfully advance any candidate, complete additional studies, obtain regulatory approvals, develop a product

candidate, or generate revenue from this program.

These and other risks are described more fully in PMGC's filings with

the United States Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of the Company's

Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, and its other documents subsequently

filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's website

at www.sec.gov. All forward-looking statements contained in this press release speak only as of the

date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to

reflect events that occur or circumstances that exist after the date on which they were made.

IR Contact: IR@pmgcholdings.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Jul. 01, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 01, 2026

Entity File Number

001-41875

Entity Registrant Name

PMGC Holdings Inc.

Entity Central Index Key

0001840563

Entity Tax Identification Number

33-2382547

Entity Incorporation, State or Country Code

Entity Address, Address Line One

c/o 120 Newport Center Drive

Entity Address, City or Town

Newport Beach

Entity Address, State or Province

Entity Address, Postal Zip Code

92660

City Area Code

888

Local Phone Number

445-4886

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.0001 par value

Trading Symbol

ELAB

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration